Dyslipidemia in patients with HIV
Abstract Since the introduction of highly active antiretroviral therapy (ART) in the treatment of HIV/AIDS patients, we have observed a change in the development of the disease, becoming a chronic therapeutically containable condition. The increase in survival goes together with associated...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Artículo revista |
| Lenguaje: | Español |
| Publicado: |
Escuela de Salud Pública y Ambiente. Fac. Cs. Médicas UNC
2015
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/RSD/article/view/11733 |
| Aporte de: |
| id |
I10-R360-article-11733 |
|---|---|
| record_format |
ojs |
| spelling |
I10-R360-article-117332025-04-03T12:06:56Z Dyslipidemia in patients with HIV Dislipemias en Pacientes VIH Dislipidemias em pacientes HIV Puppo, D. Torales M., J. Duarte, S. Pandolfi, M. Human Immunodeficiency Virus HIV – Acquired immunodeficiency syndrome. Antiretroviral therapy. Dyslipidemias Virus de Inmunodeficiencia Humana. Sindrome de InmunoDeficiencia adquirida. Terapia antirretroviral. Dislipemias Abstract Since the introduction of highly active antiretroviral therapy (ART) in the treatment of HIV/AIDS patients, we have observed a change in the development of the disease, becoming a chronic therapeutically containable condition. The increase in survival goes together with associated diseases; cardiovascular ones have become relevant, being earlier and more severe. Dyslipidemias have a leading role in this pathology. In this work, we analyze their incidence and characteristics in HIV patients, with and without ART treatment. Lipid profile was different in the pre-treatment stage (low HDL, low total Cholesterol and normal TG) from the stage under ART (marked increase of TG and to a lesser extent of total Cholesterol and LDL), with a significant association of the use of Protease Inhibitors (PIs) and CD4 levels lower than 200/mm3. Desde la introducción de la terapia antirretroviral de alta efectividad (TARV) en el tratamiento de los enfermos VIH/ SIDA, se asistió a un cambio en la evolución de la enfermedad, transformándola en una entidad crónica y terapéuticamente contenible. El aumento de la sobrevida, se acompañó de enfermedades asociadas, cobrando relevancia las cardiovasculares, más precoces y severas. Las dislipemias tienen un papel de primer orden en esta patología. En el presente trabajo se analizan su incidencia y características en infectados por VIH, con y sin tratamiento con TARV. El patrón lipídico difirió en la etapa pre-tratamiento (HDL bajo, Col. total bajo y TG normales) y bajo TARV (aumento notorio de los TG y en menor medida del Col.T y LDL), con una asociación significativa con el uso de Inhibidores de Proteasa (IP) y niveles de CD 4 menores de 200/mm3. Palabras clave: Virus de Inmunodeficiencia Humana. Sindrome de InmunoDeficiencia adquirida. Terapia antirretroviral. Dislipemias. Resumo: Desde a introdução da terapia anti-retroviral de alta eficácia (TARV) no tratamento de pacientes com HIV / AIDS, ocorreu uma mudança no curso da doença, tornando-se uma entidade crônica, terapeuticamente controlável. O aumento da sobrevida foi acompanhada por doenças associadas, fazendo destaque aquelas de origem cardiovascular, mais precozes e mais graves. As dislipidemias têm um papel de liderança nesta patologia. Neste estudo são analisadas a incidência e as características de infectados pelo HIV, com e sem tratamento com TARV. O padrão lipídico diferiu na etapa de pré-tratamento (HDL baixo, Colesterol Total baixo e TG normal) e baixo TARV (aumento marcado dos TG e, em menor medida do Colesterol Total e do LDL), com associação significativa com o uso de Inibidores da Protease (IP) e níveis do CD 4 abaixo de 200 / mm3. Escuela de Salud Pública y Ambiente. Fac. Cs. Médicas UNC 2015-07-14 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion application/pdf https://revistas.unc.edu.ar/index.php/RSD/article/view/11733 10.31052/1853.1180.v18.n3.11733 Revista de Salud Pública; Vol. 18 Núm. 3 (2014); 8-14 1852-9429 1853-1180 10.31052/1853.1180.v18.n3 spa https://revistas.unc.edu.ar/index.php/RSD/article/view/11733/12106 Derechos de autor 2015 Universidad Nacional de Córdoba https://creativecommons.org/licenses/by-nc/4.0 |
| institution |
Universidad Nacional de Córdoba |
| institution_str |
I-10 |
| repository_str |
R-360 |
| container_title_str |
Revista de Salud Pública |
| language |
Español |
| format |
Artículo revista |
| topic |
Human Immunodeficiency Virus HIV – Acquired immunodeficiency syndrome. Antiretroviral therapy. Dyslipidemias Virus de Inmunodeficiencia Humana. Sindrome de InmunoDeficiencia adquirida. Terapia antirretroviral. Dislipemias |
| spellingShingle |
Human Immunodeficiency Virus HIV – Acquired immunodeficiency syndrome. Antiretroviral therapy. Dyslipidemias Virus de Inmunodeficiencia Humana. Sindrome de InmunoDeficiencia adquirida. Terapia antirretroviral. Dislipemias Puppo, D. Torales M., J. Duarte, S. Pandolfi, M. Dyslipidemia in patients with HIV |
| topic_facet |
Human Immunodeficiency Virus HIV – Acquired immunodeficiency syndrome. Antiretroviral therapy. Dyslipidemias Virus de Inmunodeficiencia Humana. Sindrome de InmunoDeficiencia adquirida. Terapia antirretroviral. Dislipemias |
| author |
Puppo, D. Torales M., J. Duarte, S. Pandolfi, M. |
| author_facet |
Puppo, D. Torales M., J. Duarte, S. Pandolfi, M. |
| author_sort |
Puppo, D. |
| title |
Dyslipidemia in patients with HIV |
| title_short |
Dyslipidemia in patients with HIV |
| title_full |
Dyslipidemia in patients with HIV |
| title_fullStr |
Dyslipidemia in patients with HIV |
| title_full_unstemmed |
Dyslipidemia in patients with HIV |
| title_sort |
dyslipidemia in patients with hiv |
| description |
Abstract Since the introduction of highly active antiretroviral therapy (ART) in the treatment of HIV/AIDS patients, we have observed a change in the development of the disease, becoming a chronic therapeutically containable condition. The increase in survival goes together with associated diseases; cardiovascular ones have become relevant, being earlier and more severe. Dyslipidemias have a leading role in this pathology. In this work, we analyze their incidence and characteristics in HIV patients, with and without ART treatment. Lipid profile was different in the pre-treatment stage (low HDL, low total Cholesterol and normal TG) from the stage under ART (marked increase of TG and to a lesser extent of total Cholesterol and LDL), with a significant association of the use of Protease Inhibitors (PIs) and CD4 levels lower than 200/mm3. |
| publisher |
Escuela de Salud Pública y Ambiente. Fac. Cs. Médicas UNC |
| publishDate |
2015 |
| url |
https://revistas.unc.edu.ar/index.php/RSD/article/view/11733 |
| work_keys_str_mv |
AT puppod dyslipidemiainpatientswithhiv AT toralesmj dyslipidemiainpatientswithhiv AT duartes dyslipidemiainpatientswithhiv AT pandolfim dyslipidemiainpatientswithhiv AT puppod dislipemiasenpacientesvih AT toralesmj dislipemiasenpacientesvih AT duartes dislipemiasenpacientesvih AT pandolfim dislipemiasenpacientesvih AT puppod dislipidemiasempacienteshiv AT toralesmj dislipidemiasempacienteshiv AT duartes dislipidemiasempacienteshiv AT pandolfim dislipidemiasempacienteshiv |
| first_indexed |
2024-09-03T22:24:38Z |
| last_indexed |
2025-05-10T05:18:50Z |
| _version_ |
1841584693542125568 |